Free Trial

Poseida Therapeutics (NASDAQ:PSTX) Receives "Buy" Rating from HC Wainwright

Poseida Therapeutics logo with Medical background

HC Wainwright restated their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX - Free Report) in a research note published on Friday,Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock.

Poseida Therapeutics Price Performance

Shares of PSTX stock traded down $0.38 during trading hours on Friday, reaching $2.83. The stock had a trading volume of 427,940 shares, compared to its average volume of 563,527. The stock's fifty day simple moving average is $2.81 and its 200 day simple moving average is $2.91. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68. Poseida Therapeutics has a 12 month low of $1.87 and a 12 month high of $4.27. The firm has a market capitalization of $275.81 million, a PE ratio of -4.78 and a beta of 0.54.

Hedge Funds Weigh In On Poseida Therapeutics

Several hedge funds have recently modified their holdings of PSTX. Marshall Wace LLP acquired a new position in Poseida Therapeutics during the 2nd quarter valued at about $31,000. Bayesian Capital Management LP purchased a new stake in Poseida Therapeutics in the 1st quarter valued at about $33,000. Rothschild Investment LLC purchased a new stake in Poseida Therapeutics during the 2nd quarter worth approximately $35,000. Principal Financial Group Inc. acquired a new stake in Poseida Therapeutics in the 2nd quarter valued at about $35,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Poseida Therapeutics in the 3rd quarter valued at approximately $46,000. Hedge funds and other institutional investors own 46.87% of the company's stock.

Poseida Therapeutics Company Profile

(Get Free Report)

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.

Read More

Should you invest $1,000 in Poseida Therapeutics right now?

Before you consider Poseida Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Poseida Therapeutics wasn't on the list.

While Poseida Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Former Trump Advisor: Expect REITs to Soar Under Trump’s Next Presidency
Super Micro’s Rebound: Can SMCI Stock Rally Another 100%?
Why Meta Is Still a Top Stock Pick for 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines